Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	0.49	1.06	-0.23	1.11	1.09
Revenue Growth (YoY)	-54.32%	-	-	1.78%	-
Gross Profit	0.49	1.06	-0.23	1.11	1.09
Selling, General & Admin	17.08	14.06	14.66	13.96	7.64
Research & Development	39.38	20.02	44.38	34.92	11.38
Operating Expenses	56.46	34.09	59.04	48.89	19.02
Operating Income	-55.97	-33.02	-59.27	-47.78	-17.93
Interest Expense	-	-	-	-	-0.01
Interest & Investment Income	4.56	3.35	0.03	0.02	0.02
Other Non Operating Income (Expenses)	0.01	0.31	-	-	0
EBT Excluding Unusual Items	-51.41	-29.36	-59.24	-47.76	-17.93
Pretax Income	-51.41	-29.36	-59.24	-47.76	-17.93
Income Tax Expense	0.01	0	0.01	0	0
Net Income	-51.42	-29.36	-59.25	-47.76	-17.93
Preferred Dividends & Other Adjustments	-	-	-	0.95	24.39
Net Income to Common	-51.42	-29.36	-59.25	-48.71	-42.32
Shares Outstanding (Basic)	31	19	7	7	3
Shares Outstanding (Diluted)	31	19	7	7	3
Shares Change (YoY)	59.53%	178.13%	5.45%	129.85%	96.34%
EPS (Basic)	-1.67	-1.52	-8.51	-7.38	-14.74
EPS (Diluted)	-1.67	-1.52	-8.51	-7.38	-14.74
Free Cash Flow	-42.29	-25.87	-49.93	-45.46	-12.35
Free Cash Flow Per Share	-1.37	-1.34	-7.17	-6.89	-4.30
Gross Margin	100.00%	100.00%	-	100.00%	100.00%
Operating Margin	-11517.08%	-3103.48%	-	-4308.68%	-1646.06%
Profit Margin	-10579.83%	-2759.59%	-	-4392.42%	-3884.33%
Free Cash Flow Margin	-8701.24%	-2431.77%	-	-4099.28%	-1133.45%
EBITDA	-55.82	-32.89	-59.14	-47.63	-17.82
D&A For EBITDA	0.15	0.13	0.13	0.15	0.12
EBIT	-55.97	-33.02	-59.27	-47.78	-17.93
Revenue as Reported	0.49	1.06	-0.23	1.11	1.09

Updated Jun 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q